Immunomedics Inc. (IMMU)
F4Q12 Earnings Call
August 24, 2012, 10:00 am ET
Gerard Gorman - SVP, Finance & CFO
Cynthia Sullivan - President & CEO
David Goldenberg - Chairman, CSO & CMO
Boris Peaker - Oppenheimer
Ryan Martin - Lazard Capital Markets
Ling Wang - Summer Street
Welcome to Immunomedics Incorporated fourth quarter and fiscal year 2012 financial results conference call. And as a reminder, this call is being recorded. Today is Friday, August 24, 2012. With us on the call this morning are Dr. David M. Goldenberg, Chairman, Chief Scientific Officer and Chief Medical Officer; Cynthia Sullivan, President and CEO; Gerard Gorman, Senior Vice President of Finance and CFO.
I would now like to turn the conference over to Gerard Gorman, Chief Financial Officer of Immunomedics. Please go ahead.
Thank you and good morning and welcome to our first earnings conference call. I am Gerard Gorman, Senior Vice President of Finance and CFO and I thank you for participating in today’s call. I will begin with a brief summary of our current financial condition. Cynthia Sullivan, our President and CEO will follow with an overview of developments in our business and some updates on clinical programs. Finally, Dr. Goldenberg will describe our major clinical programs and research plans before we open up the call for questions and answers.
Before we begin, I would like to remind everyone that during this call, we would be making forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995.
Such statements may involve significant risks and uncertainties and actual results could differ materially from those expressed or implied in the call. For factors that could cause such differences, please refer to our regulatory filings with the SEC, most recently our annual report for the year-ended June 30, 2012.